Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 12 February 2021, 13:00 HKT/SGT

Source: Apollomics, Inc.
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
TYG100 utilizes proprietary S-TIR(TM) technology platform enabling specific B cell and T cell responses against tumor antigens

Foster City, CA & Hangzhou, CH, Feb 12, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.

TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR(TM) technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by TYG oncology Ltd. based in the United Kingdom and received support from Cancer Research UK. TYG oncology originally co-developed TYG100 with Nuance Biotech and this license is now assigned to Apollomics for further co-development.

"TYG100 represents the new era of active checkpoint control immunotherapy by enabling a rapid and appropriate natural immune response," said Guo-Liang Yu, Ph.D., Chief Executive Officer of Apollomics. "In addition, the technology that powers TYG100 enables targeted induction of antibodies neutralizing G17 at the site of the tumor. While this asset is early stage, we are excited about the technology and the opportunity to run preclinical studies and advance it into the clinic for the treatment of gastroenterological cancers."

Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China and South Africa. Nuance Biotech received an upfront cash payment and will be eligible to receive from us potential development milestone payments. TYG oncology will be eligible to receive from us tiered royalties on net sales. Apollomics will be responsible for all costs related to development, regulatory approvals, and commercialization activities for TYG100 in the territories.

Jian Ni, Chief Executive Officer, Nuance Biotech added, "ACCI is the next generation immunotherapy beyond checkpoint inhibitors, and opens the door to new anti-cancer treatments. Preclinical data support stimulation of significant immune response and studies in non-human primates have been well-tolerated and demonstrated predicted ability to achieve a high level of immune stimulation."

"We appreciate the help that Nuance has provided in getting TYG100 to the next stage of development with Apollomics. We are pleased to have such a strong partner to potentially carry TYG100 into the clinic to patients," concluded Fred Jacobs, Chief Executive Officer, TYG Oncology.

About TYG100

TYG100 is an active checkpoint control immunotherapy (ACCI) recombinant vaccine that targets the gastrin immunogen. In preclinical studies, TYG100 has induced neutralizing antibodies against gastrin, a major growth factor for pancreatic and other forms of gastrointestinal cancer. For additional information, please visit

About Apollomics, Inc.

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit

Apollomics Contacts:

Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436

U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386

China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763

Phoenix Fung
Assistant Vice President
(852) 3150 6773

Topic: Press release summary
Source: Apollomics, Inc.

Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Apollomics, Inc.
Jan 12, 2022 09:25 HKT/SGT
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
Jan 4, 2022 10:10 HKT/SGT
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Nov 22, 2021 10:40 HKT/SGT
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Oct 1, 2021 10:00 HKT/SGT
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
Aug 10, 2021 11:53 HKT/SGT
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
May 20, 2021 13:36 HKT/SGT
Mar 9, 2021 10:35 HKT/SGT
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
Mar 4, 2021 11:30 HKT/SGT
Feb 11, 2021 11:00 HKT/SGT
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Feb 10, 2021 10:10 HKT/SGT
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: